The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche
oleh: C Main, M Pitt, T Moxham, K Stein
| Format: | Article |
|---|---|
| Diterbitkan: | NIHR Journals Library 2010-10-01 |
Deskripsi
No description available for this item.